Treatment category · Emerging applications · Off-label
Toxin-based treatments
for men’s sexual health
Botulinum toxin (Botox) is being studied for several male sexual health applications — erectile dysfunction, premature ejaculation, and Peyronie’s disease. It works by temporarily relaxing targeted muscle tissue, and early research is genuinely promising in places, but this remains one of the least-studied categories on this site.
A 2024 systematic review searching three major databases found only 9 studies across all three applications combined that met basic inclusion criteria — 6 on erectile dysfunction, 2 on premature ejaculation, and just 1 on Peyronie’s disease. That’s a small evidence base to build confident expectations on.
How it works
What botulinum toxin actually does here
Botulinum toxin (the active ingredient in Botox®) works by temporarily blocking nerve signals to targeted muscle tissue, causing it to relax. Its established, FDA-approved uses include cosmetic wrinkle reduction and treatment of overactive bladder — a urologic condition, though distinct from the sexual health applications covered here.
In men’s sexual health specifically, researchers have investigated injecting it into penile or pelvic floor tissue with the goal of relaxing smooth muscle to support blood flow (for ED), relaxing the muscles involved in ejaculation (for PE), or reducing scar-tissue-related curvature (for Peyronie’s disease). None of these are FDA-approved indications — all use is off-label.
A comprehensive 2024 systematic review searched PubMed, Cochrane, and EMBASE and found only 9 studies across all three applications that met inclusion criteria — a genuinely small foundation for a category covering three distinct conditions.
The review’s own conclusion: “current evidence is limited by small, heterogeneous studies and the absence of large randomized controlled trials.” That’s the honest starting point for everything below.
The three applications
What the research shows for each condition
Erectile Dysfunction
Botulinum toxin injected into the corpus cavernosum has been studied as a way to relax smooth muscle and support blood flow for vasculogenic ED. Across the studies reviewed, erectile function scores (IIEF-EF) improved in 41–57.4% of treated patients, with benefits reported lasting up to 6 months.
41–57.4% improved (IIEF-EF) Benefits up to 6 months 6 studies in 2024 reviewPremature Ejaculation
Botulinum toxin has been studied injected into the bulbospongiosus muscle or the penile prepuce/subcoronal region, aiming to delay ejaculation by relaxing muscles involved in the reflex. This is the application with the most conflicting published evidence on this page.
Effects diminish by 6 months 10.9% adverse event rate in one studyA 2026 meta-analysis of bulbospongiosus injections found ejaculatory latency improved by 37.87 seconds at 1 month, but this was not statistically significant (p=.07), and the effect shrank to just 2.41 seconds by 6 months (also not significant). Adverse events occurred in 10.9% of patients — mostly erectile dysfunction and urinary disorders. A separate, larger 2026 meta-analysis of 8 RCTs (742 patients) found a statistically significant improvement of 17.63 seconds overall (p=0.02). Two well-conducted reviews of overlapping literature reached different conclusions — a clear sign this question isn’t settled yet.
Peyronie’s Disease
Botulinum toxin has also been explored for Peyronie’s disease, aiming to reduce plaque-related curvature and pain. The 2024 systematic review found only a single study meeting inclusion criteria for this specific application — making it, by a wide margin, the least-studied use of the three covered on this page.
Just 1 study met review criteriaDedicated treatment pages
Read the full page for any specific use
The three applications above (ED, PE, Peyronie’s) all involve injection into or near the penis itself. Botulinum toxin is also used for two other men’s sexual health applications with different anatomical targets and their own evidence bases — covered on their own dedicated pages below.
Priapus Toxin™ (Bocox)
Which of these two names is actually trademarked, the real IIEF-EF improvement data, and how it’s dosed and administered.
Scrotox
The randomized trial that reversed an earlier promising pilot study on scrotal pain, plus real fertility safety research.
Toxin for Anal Sphincter Relaxation
Real anal fissure evidence this technique is based on, honestly separated from the elective comfort use it’s more commonly sought for.
Safety profile
What’s actually been reported
Across the studies reviewed, botulinum toxin for these applications has generally been described as having a favorable safety profile — but real adverse events have been documented and shouldn’t be glossed over.
Common questions
Frequently asked questions
Is Botox for sexual health FDA-approved?
No. Botox is FDA-approved for cosmetic use, chronic migraine, and overactive bladder, among other indications — but not for erectile dysfunction, premature ejaculation, or Peyronie’s disease. All use for these three applications is off-label. Off-label use is legal and common in medicine, but it means the FDA has not reviewed evidence specifically for these uses.
Why do the two premature ejaculation studies disagree?
Different meta-analyses pooled somewhat different sets of underlying studies, used different statistical methods, and the underlying trials themselves used different injection sites, doses, and patient populations. This kind of disagreement between reviews is a real signal that the evidence base is still too small and heterogeneous to draw firm conclusions — exactly what both reviews’ authors said themselves.
Which of the three applications has the strongest evidence?
Erectile dysfunction has the most published studies (6 in the 2024 review) and the most consistent positive signal — improvement in a meaningful proportion of patients, lasting up to 6 months. Premature ejaculation has more conflicting results between reviews. Peyronie’s disease has the least evidence by far, with only a single study meeting inclusion criteria as of the most recent comprehensive review.
How long do effects last?
Based on published studies, effects are temporary and tend to diminish over months rather than being permanent — for ED, benefits have been reported lasting up to 6 months; for PE, effects in at least one study largely faded by 6 months. This is consistent with how botulinum toxin works elsewhere in medicine, where repeat treatment is typically needed to sustain results.
Considering a toxin-based treatment?
Given how limited the evidence base still is, a detailed conversation with a specialist is especially important here. Search our directory or ask in the forum first.
Key sources: Henriques et al., “A Systematic Review on Administration of Botulinum Toxin in the Management of Male Sexual Dysfunctions,” Andrology (2024) · “Clinical Efficacy and Safety of Botulinum Toxin A Injection into the Bulbospongiosus Muscle for Treating Lifelong Premature Ejaculation: A Systematic Review and Meta-Analysis” · “Efficacy of Botulinum Toxin Injections for Erectile Dysfunction and Premature Ejaculation: A Meta-Analysis of Randomized Controlled Trials” (2026) · “Intra-Cavernosal Injection of Botulinum Toxin in the Treatment of Erectile Dysfunction: a Systematic Review and Meta-Analysis”
PhallusMD is an informational resource and does not provide medical advice, diagnosis, or treatment recommendations. Botulinum toxin use for erectile dysfunction, premature ejaculation, and Peyronie’s disease is off-label and not FDA-approved for these indications. Evidence assessments reflect published literature as of 2026 and may change as new research emerges.